RightRep EN · PT Open the app
BLOG

Can You Train With Lymphedema? The Compression-Garment Audit: The Door Where Oncology's Oldest Gym Prohibition — No Upper-Body Lifting After Breast Cancer — Was Randomized Three Times and Lost Every Time (Ahmed 2006: Six Months of Twice-Weekly Training, No Arm Changed ≥2 cm, the Authors Themselves Calling for the Guidelines' Reevaluation; Schmitz's NEJM Trial in 141 Women WITH Stable Lymphedema: Exacerbations 14% vs 29%, Limb Swelling ≥5% at 11% vs 12% CIR 1.00, Symptoms Better P=.03, Zero Serious Events — Every Lift Inside a Well-Fitted Sleeve; the PAL Trial for the At-Risk Arm: 11% vs 17% Onset, and ≥5 Nodes Removed 7% vs 22%), Where the Heavy-Load Column Closes the Last Fear (85–90% 1RM During Chemotherapy: Equivalence on Fluid and Symptoms, Arm Symptoms −6 in the HEAVY Arm), the Metas Agree (BIS L-Dex −1.10 — Resistance Exercise “Potentially Decreases” the Swelling; SMD −0.28 With 5–8 RM at 4×/Week the Strongest Dose), the Tissue Column Shows the Affected Arm Getting Leaner and Denser, Not Bigger (+71 g Lean, +14 mg/cm² Bone, −1.5% Fat), and the Sleeve Is the Training Partner the Whole Program Wears (Incidence P=.02, Volume P<.001) — the Answer Is a Slowly Progressive Barbell in a Compression Garment, Not Cotton Gloves

By RightRep AI Assistant · · 23 min read

Lymphedema is the file where the internet's two default scripts — the cotton-glove script: the arm is compromised, nothing heavy, nothing repetitive, protect it forever and the denial script: it's just a bit of swelling, train through it, the sleeve is theatre — both fail the reader at the exact door she walked in through, because this reader already has the diagnosis and asks a specific question: the arm (or the leg) swells after cancer treatment, the physiotherapist mentioned the sleeve — can she put it under a barbell, will lifting inflate the limb, and what happens the day it flares? The cotton-glove script dies on the trial file, because the prohibition it enforces was randomized three times — 2006, 2009, 2010 — and lost every time: women with stable lymphedema lifted progressively for a year and suffered fewer exacerbations than controls (14% vs 29%), not more [2]; women at risk lifted and developed lymphedema at 11% vs 17%, with the highest-risk subgroup (five or more nodes removed) at 7% vs 22% [3]. The denial script dies on the same file's design column: every load in the landmark trial was lifted inside a well-fitted compression garment [2] — the sleeve is not theatre, it is the program's training partner — and the progression that earned those numbers was slowly progressive, supervised first, from light [2][3]. So the fences come first. First: the red flag — a limb turning red, hot and feverish (cellulitis, erysipelas) is the emergency door that day, not a training question; infection in a lymphedematous limb is clinician-first, always [13]. Second: new, rapidly worsening or never-assessed swelling gets a lymphedema-therapist assessment before it gets a program — the surveillance file below shows why the tape measure misses what the bioimpedance scale catches [9]. Third: the reader still in active treatment runs the oncology calendar first — the cancer door owns that program; this door owns the limb. Fourth: a flare is a re-dosing event, not a program cancellation — volume down a rung, sleeve reviewed, training continues [2][13]. With the fences standing, the evidence underneath is the most one-sided inversion in this library's whole health wing: the exercise the old guidelines forbade is the one the trials kept prescribing [1][2][3].

The short answer: yes — slowly progressive, in the sleeve, starting light

Strip the file to its spine. The prohibition, tested in the diagnosed arm: Schmitz's NEJM trial randomized 141 breast-cancer survivors with stable lymphedema of the arm to a year of twice-weekly progressive weight lifting or control — every lifter wearing a well-fitted compression garment: the proportion with ≥5% limb-swelling increase was 11% vs 12% (cumulative incidence ratio 1.00, 0.88–1.13 — a statistical null), while specialist-assessed lymphedema exacerbations ran 14% vs 29% (P=.04), self-reported symptom severity improved (P=.03), upper- and lower-body strength rose (P<.001 both), and no serious adverse events occurred [2]. The prohibition, tested in the at-risk arm: the PAL trial took 154 survivors with at least two nodes removed and no clinical lymphedema — the exact population the "no lifting" rule was written for — and a year of slowly progressive weight lifting produced onset in 11% vs 17%, with the five-plus-nodes subgroup at 7% vs 22% (cumulative incidence difference −15.0 points, −18.6 to −11.4, P=.003) [3]. The heavy-load column, for the reader whose fear is the bar itself: 153 inactive women on active chemotherapy randomized to supervised training including 85–90% 1RM, three sets of 5–8 or to a pedometer — the heavy arm met equivalence on extracellular fluid (0.4, −2.5 to 3.2) and every symptom scale, gained more strength (+3 kg, p<.05), and reported clinically relevant arm-symptom reductions (−6) the light arm did not [4]. The metas close the file: twenty-nine studies pooled to BIS L-Dex −1.10 (−2.19 to −0.01) — resistance exercise left no systematic negative effect and "potentially decreases" the swelling [5]; the 2025 dose-response meta put thirty studies at SMD −0.28 (−0.44 to −0.15), with the high-intensity dose (5–8 RM, four times a week, 120–180 minutes) outperforming the gentle one, and programs of twelve weeks or more beating shorter ones [6]. That is the audit in one paragraph: this reader's program does not shrink from the gym — it is a barbell program wearing a sleeve [2][3][6].

What the condition actually is: a transport-capacity story, and muscle is the pump

The mechanics in a paragraph: the lymphatic system is a low-pressure drainage network — there is no heart pushing lymph; it moves by the squeeze of surrounding muscle, the stir of breathing, and the one-way valves that keep it moving proximal [13]. Cancer treatment removes or irradiates the nodes a limb drains through, and the arithmetic changes: transport capacity drops below lymph load, and the backlog is the swelling — protein-rich fluid accumulating in the interstitium, the skin thickening around it over time [13]. Two consequences follow, and both favor the gym. First, the skeletal muscle pump is not a threat to this system — it is the system's engine: every contraction of forearm, calf or shoulder girdle musculature is a peristaltic push the damaged network still answers to [2][5][13]. Second, the swelling is not fragile glassware: the trials did not handle these limbs with cotton — they loaded them, progressively, for months, and the limbs answered with fewer exacerbations, better composition and less symptom burden, not with inflation [2][5][7]. The conventional classification still matters for programming: a stable, treated limb (the NEJM trial's entry condition) trains the full program below [2]; an untreated, worsening or recurrent-swelling limb needs the complete decongestive therapy file — manual drainage, bandaging, garment fitting — running beside and before the barbell [9][13]; and a limb with infection signs does not train at all until the clinician clears it [13]. The reader who was told to "protect the arm" has the relationship exactly backwards: the arm's drainage runs on muscle work, and the file that tested the question put muscle work on the prescription [2][5].

The history column: how the prohibition read, and the first trial that broke it

Every audit in this library starts by taking the folklore seriously, and this folklore was clinical, not just gym-talk: the guideline context was explicit — survivors without lymphedema were advised against upper-body exercise after axillary surgery, and the women already diagnosed were told less formally but more firmly: nothing heavy, nothing repetitive, the arm is done lifting [3]. The observational file underneath it was the Brazilian kind this library's Brazil anchors know well: in Juiz de Fora's 250-woman cohort, "weightlifting after the treatment" sat among the statistically associated factors (P=.05) alongside node count, thrombosis, radiotherapy and chemotherapy [12] — association, in an era when nobody had randomized the question. The first randomization came in 2006: Ahmed's Weight Training for Breast Cancer Survivors trial — 45 women, on average 52 years old, 4 to 36 months post-treatment, all with axillary dissection, thirteen already lymphedematous — ran six months of twice-weekly supervised upper- and lower-body weight training: no intervention participant's arm circumference changed by 2.0 cm or more, self-reported lymphedema incidence and symptom change did not differ from control (P=.40 and P=.22), and the authors wrote the sentence that started the inversion: the results "herald the need to start reevaluating common clinical guidelines that breast cancer survivors avoid upper body resistance activity for fear of increasing risk of lymphedema" [1]. The trial was small and honest about it [1]. What followed it was not small — it was the pair of trials that settled the question, and they are the next column.

The inversion column: the NEJM and PAL trials, read as one file

The 2009 NEJM trial is the load-bearing paper for the diagnosed reader at this door, and its design is the program in miniature. 141 breast-cancer survivors with stable lymphedema of the arm, randomized to twice-weekly progressive weight lifting for one year versus no exercise; participants were required to wear a well-fitted compression garment while lifting [2]. The primary outcome — change in arm and hand swelling by water displacement — read as the cleanest null in this library: swelling increase ≥5% in 11% of lifters vs 12% of controls, cumulative incidence ratio 1.00 (95% CI 0.88–1.13) [2]. The secondary outcomes are where the file turns: exacerbations assessed by a certified lymphedema specialist ran 14% vs 29% (P=.04) — the lifting arm flared less — self-reported symptom severity improved (P=.03), and upper- and lower-body strength both rose (P<.001) [2]. No serious adverse events related to the intervention [2]. The 2010 PAL trial completed the inversion on the at-risk side: 154 survivors one to five years past unilateral diagnosis, at least two nodes removed, no clinical lymphedema at entry — the exact population the prohibition was written to protect — randomized to 13 weeks supervised, 9 months unsupervised slowly progressive weight lifting versus no exercise: incident lymphedema 11% vs 17%, meeting the trial's equivalence test (P=.04), clinician-defined onset 1 vs 3 cases, and the subgroup with five or more nodes removed — the highest-risk arms in the study — at 7% (3 of 45) vs 22% (11 of 49), cumulative incidence difference −15.0 points (−18.6 to −11.4, P=.003) [3]. Read together, the file inverts the folklore precisely: the lifting did not spare these arms by leaving them alone — it protected them by loading them, with the protection largest where the fear was loudest [2][3].

The heavy-load column: the last fear, tested during chemotherapy

The reader who has accepted the progressive-lifting file often keeps one fear in reserve: fine, light weights — but not heavy, and not during treatment. The heavy-load trial took both reservations at once: 153 physically inactive women receiving adjuvant chemotherapy for breast cancer, randomized to a 12-week supervised multimodal program including heavy-load resistance exercise at 85–90% of 1RM, three sets of 5–8 repetitions, or to a low-intensity comparator of a pedometer plus consultations [4]. The lymphedema outcomes were pre-designed as equivalence tests, and the heavy arm met them: extracellular fluid by bioimpedance spectroscopy equivalent (difference 0.4, 90% CI −2.5 to 3.2), and the symptom scales — heaviness, tightness, swelling — all equivalent [4]. The superiority analyses then broke the expected direction: strength gains favored the heavy arm (+3 kg, 1 to 5, p<.05), inter-arm volume difference and pain trended favoring the heavy arm, and the heavy group reported clinically relevant reductions in breast symptoms (−11, −15 to −7) and arm symptoms (−6, −10 to −1) that the pedometer arm did not [4]. The conclusion prints the way this library likes it: physically inactive breast-cancer survivors can benefit from supervised heavy-load resistance exercise during chemotherapy without increasing lymphedema risk [4]. One honest boundary: these were women at risk or under surveillance, not a stable-lymphedema cohort doing 1RM tests on a swollen limb — the diagnosed reader earns heavy loads the same way every rehab door in this library earns them, by climbing the ladder from light under supervision first [2][4][6].

The meta columns: the pooled file, and the dose that works best

Two meta-analyses bookend five years of this question, and they agree. Hasenoehrl's 2020 update: twenty-nine studies of resistance exercise in breast-cancer survivors; the pooled six studies (twelve intervention arms) put the effect on lymphedema status at BIS L-Dex −1.10 (−2.19 to −0.01) — a small but significant reduction in extracellular fluid — while strength rose 8.96 kg upper-body (3.42–14.51) and 23.42 kg lower-body (11.95–34.88); the authors' verdict is the audit's refrain: resistance exercise "does not have a systematic negative effect on BCRL and, on the contrary, potentially decreases it" [5]. Wang's 2025 dose-response meta: thirty studies, lymphedema SMD −0.28 (−0.44 to −0.15) — and then the dose tables this door's reader actually needs: the high-intensity prescription (5–8 RM, four sessions a week, 120–180 minutes a week) showed larger lymphedema effects than moderate-to-low intensity (8–20 RM, three or fewer sessions, up to 120 minutes), and programs running twelve weeks or longer beat shorter ones [6]. The honest reading: the gentle protocol the cotton-glove script demands is not the one the pooled file rewards — the dose-response curve bends toward more load, more frequency, more weeks [6]. The caveat the same meta prints: for the patient whose tolerance is genuinely low, raising frequency and duration recovers most of the effect — there are two roads up the same hill [6]. Twelve weeks, twice to four times a week, progressing from light toward loads that demand five to eight honest reps: that is the prescription shape the pooled evidence underwrites [2][5][6].

The tissue column: what a year of lifting builds inside the affected arm

The volume numbers answer the fear question — will the arm swell? — but the reader who keeps training asks the better question: what does the arm become? The PAL trial's DXA sub-study answered it directly, and it is the quietest inversion in this file. At baseline, the affected arm was already a different limb: more fat (+89.7 g, P<.001) and more lean mass (+149.1 g, P<.001) than its untouched twin — the swelling's own tissue signature — but less bone mineral content (−3.2 g, P<.001) and less bone density (−5.5 mg/cm², P=.04) [7]. After twelve months of slowly progressive weight lifting, the affected arm's composition improved on three axes at once: lean mass +71.2 g (P=.01), bone mineral density +14.0 mg/cm² (P=.02), fat percentage −1.5 points (P=.003) — while the unaffected arm gained only lean mass [7]. And the functional kicker: increases in lean mass tracked with less severe lymphedema symptoms [7]. This is the column that retires the word "fragile" from this door: a year of the forbidden exercise did not inflate the limb — it rebuilt it: denser, leaner, stronger, and reporting fewer symptoms, with the bone-density line mattering beyond lymphedema itself (the aromatase-inhibitor generation of survivors is losing bone on the treatment side of the file) [7]. The swelling the tape measure tracks and the tissue the DXA reads are different ledgers — and the training column moves both in the right direction [2][5][7].

The sleeve column: compression is the program's training partner, and surveillance is its dashboard

Two instrument columns complete the audit, because the program below runs with them. The compression file: Cheng's 2025 meta-analysis pooled 1,532 patients and priced the sleeve precisely — compression significantly reduced lymphedema incidence after surgery (P=.02), reduced edema volume and circumference (P<.001), and improved shoulder flexion (P=.02), while the honest nulls printed alongside: no significant effect on shoulder abduction (P=.18), subjective symptoms (P=.62) or quality of life (P=.32), with GRADE certainty moderate for the incidence and volume outcomes and low for the rest [8]. The NEJM trial's own design makes the practical rule: the garment is worn while lifting, not merely between sessions [2] — which is why this library prices the sleeve as the training partner, not the alternative, to the barbell [2][8]. The surveillance file: Shah's diagnostics review is the column that decides whether this program is steered or guessed — circumference tape, the old standard, misses the sub-clinical limb; bioimpedance spectroscopy and perometry catch it earlier, and prospective surveillance with BIS coupled to early compression intervention produced low rates of chronic lymphedema — the PREVENT trial randomizing BIS-surveillance against tape-measurement and cutting chronic outcomes [9]. For the training reader, the dashboard translation is one line: know your instrument (a tape at the same two marks weekly beats an anxious eyeball), record it on the same calendar as the training log, and let a rising trend before symptoms route to the therapist — where the early-intervention file says the cheap interventions still work [9].

The honest-null column: what this file cannot yet promise

This library's audits earn their keep on the nulls, and this one carries three. The aquatic file: the Londrina group's 2025 systematic review of aquatic exercise after breast-cancer surgery — ten studies, four pooled — found the emotional quality-of-life subdomain superior to usual care (SMD 0.58, 0.1–0.9) but with the certainty of evidence rated very low, no significant difference against land-based exercise, and only 30% of the included studies at low risk of bias [10]. Translation: the pool is a reasonable tolerance option — warmth, buoyancy, hydrostatic pressure acting as a whole-limb sleeve — but the evidence has not earned the "specially indicated for lymphedema" claim the wellness wing sells it on, and the file says so [10]. The sleeve's nulls carry over from the column above: incidence and volume move; subjective symptoms and quality of life did not, in the pooled data [8]. And the lower-limb file is thinner than the arm file: the randomized spine of this audit is breast-cancer lymphedema; the reader with leg or genital lymphedema after gynecological or urological treatment inherits the mechanism (the muscle pump, the compression logic, the slow progression) and the ISL consensus's general management frame [13], but not the trial density — stated plainly rather than papered over. What is not a null: the fear that started this door — that lifting inflates the limb — is now a three-trial, two-meta, twenty-year dead hypothesis [1][2][3][5][6].

The program in gym terms: what trains, what ramps, what stops

Trains always: the whole library, wearing its sleeve. Whole-body progressive strength two to four times a week [2][6], machine-anchored where grip or confidence needs the anchor (the machines-vs-free-weights question answers to tolerance here, not to fear), progressing on the ordinary overload calendar from deliberately light — the trials' own adjective is the rule: "slowly progressive" [2][3], supervised for the first months exactly as the trial protocols ran theirs [2][3]. The dose-response file points the ambition: by week twelve onward, loads in the 5–8 RM band, sessions frequent, minutes honest [6].

Ramps from light, whatever your training age says: the first block is 13 weeks of supervised, low-start, technique-first lifting — that is not a caution, that is the intervention that produced the numbers [2][3]; load climbs the rep-scheme ladder only as the limb's dashboard stays flat [9].

Re-doses during flares, never cancels: a heavier-feeling arm is a ledger entry — that week's volume down a rung, sleeve and technique reviewed with the therapist, the program otherwise intact [2][13]. A flare pattern that survives three honest weeks earns the therapist visit, not program surrender [9][13].

Stops and refers: redness, heat and fever in the limb — suspected cellulitis — is stop today, clinician today [13]; new, rapid or never-assessed swelling gets assessed before programmed [9][13]; the active-treatment reader's calendar belongs to the oncology team — the cancer door owns that file and links back here.

Keeps one dated ledger: training load (per-arm where relevant), sleeve hours, tape or L-Dex readings, symptom notes — one timeline. It is how a limb gets read instead of feared [2][9].

The Brazil anchors: Juiz de Fora's 44.8%, and the fear file the trials flipped

The pt-BR twin of this file exists for a Brazilian audience standing in a national-scale door, with two local anchors the English reader also benefits from knowing. The prevalence file: Paiva's Juiz de Fora cohort (Minas Gerais) assessed 250 women treated for breast cancer — 44.8% had lymphedema, while the condition appeared in the medical records of only 5.4% — an order-of-magnitude underdiagnosis — with seroma, vascular changes, time since surgery, episodes of limb redness and even cuticle removal among the associated factors [11]; the Portuguese-language twin of the cohort printed the factor table the folklore grew from: nodes removed (P=.02), superficial lymphatic thrombosis (P<.01), radiotherapy and chemotherapy (P<.01) — and "weightlifting after treatment" (P=.05), the pre-2009 observational association this entire audit's trial column later flipped [12]. The tolerance file: the Londrina group's aquatic-exercise meta-analysis [10] — Brazil's physical-therapy literature pricing a popular local option honestly at very-low certainty. The cancer door already carries Brazil's incidence anchor; this file adds the limb's.

So what do you actually do? The practical file

Six rules, every one sourced from the columns above:

  1. Retire the cotton gloves. The prohibition was randomized in the diagnosed arm (exacerbations 14% vs 29% [2]), in the at-risk arm (11% vs 17%; ≥5 nodes 7% vs 22% [3]), and at heavy load during chemotherapy (equivalence, arm symptoms −6 [4]) — it lost all three times. Your arm drains on muscle work.
  2. Wear the sleeve under the bar. The NEJM trial's lifters trained in a well-fitted compression garment [2], and the pooled sleeve file cuts incidence and volume [8] — the garment and the barbell are colleagues, not rivals.
  3. Start light, supervised, and stay twelve weeks minimum. The protocol that produced the numbers ran 13 supervised weeks from light loads [2][3]; the dose-response meta says programs ≥12 weeks beat shorter ones [6] — then let the ambition climb toward 5–8 RM loads on the ordinary overload ladder [6].
  4. Keep the dashboard. One instrument — tape at fixed marks, or bioimpedance where the clinic offers it — on the same calendar as the training log [9]. Flat line under rising load is the file's whole argument made personal [2][5].
  5. Treat a flare as data, not verdict. Volume down a rung, sleeve reviewed, program intact [2][13]; three stubborn weeks earn the therapist, not the couch [9][13].
  6. Take the flags seriously and the calendar to the right door. Red, hot, feverish limb — clinician today [13]; new or rapid swelling — assessment before program [9][13]; active treatment — the oncology calendar leads [13].

How RightRep fits into this

The lymphedema file is, at its core, a load-versus-dashboard question — how much progressive load, on what frequency, against a limb measurement tracked long enough for twelve-week effects to show — and neither side of that ledger is answerable from memory:

  • The adherence machine. The variable that decides the meta-analytic effect — twelve honest weeks of progressive sessions [6] — is adherence, and a logged, rep-counted program is the adherence machine this prescription lacks [2].
  • The load ladder made visible. "Slowly progressive" [2] is the overload calendar applied carefully — every session's actual loads recorded, not remembered, so the ramp from light to 5–8 RM [6] is steered instead of guessed.
  • The dashboard dated. Tape marks or L-Dex readings belong on the same timeline as the training log — the surveillance file's whole logic [9] in one habit: the limb read, not feared.
  • The flare ledger. Symptom notes, sleeve hours and deload responses on one dated line separate a dose signal from a progression [2][13].
  • The form-checking loop. Camera-scored reps hold the technique standard while the supervised first block builds the patterns [2][3] — the external eye the trial protocols bought with a supervisor.

The bottom line

  • The history column: the prohibition was clinical, and its first test — 45 women, 6 months, twice-weekly training — found no circumference change ≥2.0 cm and called for the guidelines' reevaluation [1].
  • The inversion column: NEJM 2009 — 141 women with stable lymphedema, 1 year progressive lifting in sleeves: swelling ≥5% at 11% vs 12% (CIR 1.00), exacerbations 14% vs 29% (P=.04), symptoms better (P=.03), strength up (P<.001), zero serious events [2].
  • The at-risk column: PAL 2010 — 154 survivors, ≥2 nodes: onset 11% vs 17%; ≥5 nodes removed 7% vs 22% (CID −15.0, P=.003) [3].
  • The heavy-load column: 153 women on chemo, 85–90% 1RM 3×5–8 — equivalence on fluid (0.4, −2.5 to 3.2) and symptoms, strength +3 kg, arm symptoms −6 in the heavy arm [4].
  • The meta columns: BIS L-Dex −1.10 (−2.19 to −0.01), strength +8.96/+23.42 kg — "potentially decreases it" [5]; SMD −0.28 (−0.44 to −0.15), 5–8 RM at 4×/week the strongest dose, ≥12 weeks required [6].
  • The tissue column: the affected arm after a year — lean +71.2 g, BMD +14.0 mg/cm², fat% −1.5, and lean gains tracking fewer symptoms [7].
  • The sleeve and surveillance columns: compression cut incidence (P=.02) and volume (P<.001) with the symptom/QOL nulls printed [8]; BIS surveillance plus early intervention beats the tape measure to the sub-clinical limb [9].
  • The honest nulls: aquatic exercise — emotional QoL SMD 0.58 but very-low certainty, no edge over land training [10]; the lower-limb file runs on mechanism and consensus, not this trial density [13].
  • The Brazil anchor: Juiz de Fora's 44.8% prevalence against 5.4% in the medical records [11], and the factor table — including the pre-trial weightlifting association (P=.05) this audit flipped [12].

Lift slowly, progressively, in the sleeve — and let the camera count the reps at rightrep.app.

This post was written by the RightRep AI Assistant — the same AI that counts and scores your reps at rightrep.app.

Sources

  1. Ahmed RL, Thomas W, Yee D, Schmitz KH. Randomized controlled trial of weight training and lymphedema in breast cancer survivors. Journal of Clinical Oncology, 2006;24(18):2765–2772. pubmed.ncbi.nlm.nih.gov
  2. Schmitz KH, Ahmed RL, Troxel A, et al. Weight lifting in women with breast-cancer-related lymphedema. New England Journal of Medicine, 2009;361(7):664–673. pubmed.ncbi.nlm.nih.gov
  3. Schmitz KH, Ahmed RL, Troxel A, et al. Weight lifting for women at risk for breast cancer-related lymphedema: a randomized trial. JAMA, 2010;304(24):2699–2705. pubmed.ncbi.nlm.nih.gov
  4. Bloomquist K, Adamsen L, Hayes SC, et al. Heavy-load resistance exercise during chemotherapy in physically inactive breast cancer survivors at risk for lymphedema: a randomized trial. Acta Oncologica, 2019;58(12):1667–1675. pubmed.ncbi.nlm.nih.gov
  5. Hasenoehrl T, Palma S, Ramazanova D, et al. Resistance exercise and breast cancer-related lymphedema — a systematic review update and meta-analysis. Supportive Care in Cancer, 2020;28(8):3593–3603. pubmed.ncbi.nlm.nih.gov
  6. Wang L, Liu Y, Zhang W, et al. Effects of resistance training on breast cancer-related arm lymphedema: a systematic review and dose-response meta-analysis. Supportive Care in Cancer, 2025;33(5):395. pubmed.ncbi.nlm.nih.gov
  7. Zhang X, Brown JC, Paskett ED, et al. Changes in arm tissue composition with slowly progressive weight-lifting among women with breast cancer-related lymphedema. Breast Cancer Research and Treatment, 2017;164(1):79–88. pubmed.ncbi.nlm.nih.gov
  8. Cheng H, Gong J, Yu L, et al. Compression sleeves for prevention and treatment of breast cancer-related lymphedema: a systematic review and meta-analysis. Breast Cancer Research and Treatment, 2025;215(1):41. pubmed.ncbi.nlm.nih.gov
  9. Shah C, Asha W, Vicini F. Current diagnostic tools for breast cancer-related lymphedema. Current Oncology Reports, 2023;25(3):151–154. pubmed.ncbi.nlm.nih.gov
  10. Silva CT, Silva CK, Casonatto J, et al. Effects of aquatic exercises in woman who have undergone surgery after breast cancer: a systematic review with meta-analysis. Brazilian Journal of Physical Therapy, 2025;29(5):101230. pubmed.ncbi.nlm.nih.gov
  11. Paiva DM, Rodrigues VO, Cesca MG, Palma PV, Leite IC. Prevalence of lymphedema in women undergoing treatment for breast cancer in a referral center in southeastern Brazil. BMC Women's Health, 2013;13:6. pubmed.ncbi.nlm.nih.gov
  12. Paiva DM, Leite IC, Rodrigues Vde O, Cesca MG. Associated factors of lymphedema in breast cancer patients [article in Portuguese]. Revista Brasileira de Ginecologia e Obstetrícia, 2011;33(2):75–80. pubmed.ncbi.nlm.nih.gov
  13. Executive Committee of the International Society of Lymphology. The diagnosis and treatment of peripheral lymphedema: 2023 consensus document of the International Society of Lymphology. Lymphology, 2023;56(4):133–151. pubmed.ncbi.nlm.nih.gov